Planning for sustained treatment, including cost sustainability, is important from the outset
1 Wegovy reduced the risk of major adverse cardiovascular events, meaning cardiovascular death, non-fatal heart attack, or non-fatal stroke, by 20%
Research has shown KPV: Reduces intestinal inflammation Supports gut barrier function Modulates the immune response in inflammatory bowel conditions For long COVID patients with significant gut dysfunction and gut-driven systemic inflammation, KPV offers a targeted, well-tolerated option for reducing the gut-immune inflammatory burden
Rates of obesity worldwide have more than doubled since 1990 among adults and have increased more than fourfold among children and adolescents.[1] Obesity is associated with a number of health conditions, including:[2] High blood pressure High cholesterol Heart disease Type 2 diabetes Asthma Sleep apnea Osteoarthritis and other musculoskeletal disorders Gallstones and gallbladder disease Anxiety and depression Low self-esteem Decreased quality of life Increased risk of being bullied, especially in children and adolescents Certain types of cancer With so many potential health impacts, many people are exploring medical options to support weight loss
GPX3, a key member of the GPX family, has predominantly been investigated within oncology [23,24,25], but it has also been shown to play essential roles in pathological processes such as inflammation, fibrosis, metabolic homeostasis and insulin resistance [26,27,28]